Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Drug

HutchMed’s Sovleplenib Set for Priority Review in China for Chronic Immune Thrombocytopenia

Fineline Cube Dec 7, 2023

China’s Center for Drug Evaluation (CDE) has indicated that HutchMed (China) Ltd (NASDAQ: HCM; HKG:...

Company Drug

Trinomab’s TNM002 Antitetanus Monoclonal Antibody Filing Accepted for Review in China

Fineline Cube Dec 7, 2023

China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing...

Company Deals

BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis

Fineline Cube Dec 7, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the...

Company Drug

Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma

Fineline Cube Dec 7, 2023

Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent...

Company Deals

AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion, Strengthening Neuroscience Portfolio

Fineline Cube Dec 7, 2023

AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately...

Company Drug

Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP

Fineline Cube Dec 7, 2023

Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough...

Company Deals

Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China

Fineline Cube Dec 7, 2023

Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic...

Company Deals

Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding

Fineline Cube Dec 7, 2023

Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100...

Company Drug

Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials

Fineline Cube Dec 7, 2023

Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has...

Company Drug

Shanghai Pharmaceuticals Gains NMPA Approval for WST04 Clinical Trials in Oncology

Fineline Cube Dec 7, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer

Fineline Cube Dec 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), based in China, has announced that its market...

Company Deals

Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules

Fineline Cube Dec 7, 2023

Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm...

Company Drug

Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma

Fineline Cube Dec 7, 2023

Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Company Deals

Innovent Biologics Expands Partnership with Synaffix for New ADC Development

Fineline Cube Dec 7, 2023

Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...

Company Deals

Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection

Fineline Cube Dec 7, 2023

Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...

Company

Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition

Fineline Cube Dec 6, 2023

Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for...

Company Drug

Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Dec 6, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...

Company Deals

AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience

Fineline Cube Dec 6, 2023

AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in...

Company

J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth

Fineline Cube Dec 6, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,...

Company Drug

China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication

Fineline Cube Dec 6, 2023

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Posts pagination

1 … 374 375 376 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.